In this clinical trial, rofecoxib (25 mg per day) was studied in the prevention of recurrent colorectal cancer. Although the median duration of study treatment was only 7.4 months, rofecoxib therapy was associated with an increased risk of cardiovascular adverse events (relative risk as compared with placebo, 2.66; P=0.04). The results indicate that even short-term treatment with rofecoxib may result in cardiovascular toxicity.
More...
Linear Mode
